Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 3/20 | 0.63 |
| ▸ | YAP1 | P46937 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 8/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25790356 | 0.86 | TEAD1 (0.61) | TEAD1YAP1TNNI3KBRAF | |
| SCHEMBL20766405 | 0.86 | TEAD1 (0.66) | TEAD1YAP1TNNI3KEGFRBRAF | |
| SCHEMBL20766513 | 0.83 | TEAD1 (0.80) | TEAD1YAP1KMT2ATNNI3KEGFR | |
| SCHEMBL24496007 | 0.82 | TEAD1 (0.58) | TEAD1YAP1TNNI3KEGFRMAPT | |
| SCHEMBL29648310 | 0.82 | TEAD1 (0.58) | TEAD1YAP1TNNI3KEGFRMAPT | |
| SCHEMBL25790415 | 0.82 | TEAD1 (0.64) | TEAD1YAP1TNNI3KEGFR | |
| SCHEMBL25790336 | 0.81 | TEAD1 (0.77) | TEAD1YAP1TNNI3KSMN1; SMN2BRAF | |
| SCHEMBL20766878 | 0.81 | TEAD1 (0.67) | TEAD1YAP1TNNI3KEGFRMAPT | |
| SCHEMBL29901832 | 0.81 | TEAD1 (0.67) | TEAD1YAP1TNNI3KEGFRMAPT | |
| SCHEMBL20766326 | 0.81 | TEAD1 (0.70) | TEAD1YAP1TNNI3KEGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885YAP1 9/4885KMT2A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.